The relationship between the gut microbiota, benign prostatic hyperplasia, and erectile dysfunction.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
27
12
2021
accepted:
22
03
2022
revised:
21
03
2022
medline:
9
6
2023
pubmed:
15
4
2022
entrez:
14
4
2022
Statut:
ppublish
Résumé
Microbiota is defined as the group of commensal microorganisms that inhabit a specific human body site. The composition of each individual's gastrointestinal microbiota is influenced by several factors such as age, diet, lifestyle, and drug intake, but an increasing number of studies have shown that the differences between a healthy microbiota and a dysbiotic one can be related to different diseases such as benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The aim of this review is to give an overview of the role of the gut microbiota on BPH and ED. Gut microbiota modifications can influence prostate health indirectly by the activation of the immune system and the production of proinflammatory cytokines such as IL-17, IL-23, TNF-alpha, and IFN-gamma, which are able to promote an inflammatory state. Gut dysbiosis may lead to the onset of ED by the alteration of hormone levels and metabolic profiles, the modulation of stress/anxiety-mediated sexual dysfunction, the development of altered metabolic conditions such as obesity and diabetes mellitus, and the development of hypertension. In conclusion, much evidence suggests that the intestinal microbiota has an influence on various pathologies including BPH and ED.
Identifiants
pubmed: 35418604
doi: 10.1038/s41443-022-00569-1
pii: 10.1038/s41443-022-00569-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-355Investigateurs
Giorgio Ivan Russo
(GI)
Ioannis Sokolakis
(I)
Marco Falcone
(M)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev. 2012;70:S38–44.
pubmed: 22861806
doi: 10.1111/j.1753-4887.2012.00493.x
Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–9.
pubmed: 16741115
pmcid: 3027896
doi: 10.1126/science.1124234
Cresci GA, Bawden E. Gut microbiome. Nutr Clin Pract. 2015;30:734–46.
pubmed: 26449893
pmcid: 4838018
doi: 10.1177/0884533615609899
Suau A, Bonnet R, Sutren M, Godon J-J, Gibson GR, Collins MD, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65:4799–807.
pubmed: 10543789
pmcid: 91647
doi: 10.1128/AEM.65.11.4799-4807.1999
Lepage P, Leclerc MC, Joossens M, Mondot S, Blottière HM, Raes J, et al. A metagenomic insight into our gut’s microbiome. Gut. 2013;62:146–58.
pubmed: 22525886
doi: 10.1136/gutjnl-2011-301805
Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol. 2016;22:7186–202.
pubmed: 27621567
pmcid: 4997632
doi: 10.3748/wjg.v22.i32.7186
LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24:160–8.
pubmed: 22940212
doi: 10.1016/j.copbio.2012.08.005
Bull MJ, Plummer NT. Part 1: the human gut microbiome in health and disease. Integr Med (Encinitas). 2014;13:17–22.
pubmed: 26770121
Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108:516–20.
pubmed: 11590374
doi: 10.1067/mai.2001.118130
Sidhu M, van der Poorten D. The gut microbiome. Aust Fam Physician. 2017;46:206–11.
pubmed: 28376573
Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao J-Z, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC Microbiol. 2016;16:90.
pubmed: 27220822
pmcid: 4879732
doi: 10.1186/s12866-016-0708-5
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–8.
pubmed: 21885731
pmcid: 3368382
doi: 10.1126/science.1208344
Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol. 2009;7:887–94.
pubmed: 19898491
pmcid: 9354563
doi: 10.1038/nrmicro2245
Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362.
pubmed: 31953381
pmcid: 6969170
doi: 10.1038/s41467-019-14177-z
Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13:260–70.
pubmed: 22411464
pmcid: 3418802
doi: 10.1038/nrg3182
Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature. 2012;487:104–8.
pubmed: 22722865
pmcid: 3393783
doi: 10.1038/nature11225
Osman MM, El-Khatib FM, Roberts NH, Huynh LM, Yafi FA. The gut microbiome and men’s sexual health. Curr Sex Heal Rep. 2019;11:348–57.
doi: 10.1007/s11930-019-00230-x
Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol. 2002;167:1363–6.
pubmed: 11832733
doi: 10.1016/S0022-5347(05)65301-3
Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J. 2006;27:2640–8.
pubmed: 17056702
doi: 10.1093/eurheartj/ehl341
Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–8.
pubmed: 28888753
doi: 10.1016/j.urology.2017.08.039
Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001;87:797–805.
pubmed: 11412216
doi: 10.1046/j.1464-410x.2001.02193.x
Krsmanovic A, Tripp DA, Nickel JC, Shoskes DA, Pontari M, Litwin MS, et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J. 2014;8:403.
pubmed: 25553153
pmcid: 4277519
doi: 10.5489/cuaj.2179
Shoskes DA, Wang H, Polackwich AS, Tucky B, Altemus J, Eng C. Analysis of gut microbiome reveals significant differences between men with chronic prostatitis/chronic pelvic pain syndrome and controls. J Urol. 2016;196:435–41.
pubmed: 26930255
doi: 10.1016/j.juro.2016.02.2959
Alipour M, Zaidi D, Valcheva R, Jovel J, Martínez I, Sergi C, et al. Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis. J Crohn’s Colitis. 2016;10:462–71.
doi: 10.1093/ecco-jcc/jjv223
Kostic AD, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen A-M, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. 2015;17:260–73.
pubmed: 25662751
pmcid: 4689191
doi: 10.1016/j.chom.2015.01.001
Bosch J, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate. 2007;67:1816–24.
pubmed: 17935157
doi: 10.1002/pros.20663
Wilson JD. The critical role of androgens in prostate development. Endocrinol Metab Clin North Am. 2011;40:577–90, ix.
pubmed: 21889722
doi: 10.1016/j.ecl.2011.05.003
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol. 2014;66:619–22.
pubmed: 25012523
doi: 10.1016/j.eururo.2014.06.026
Konkol Y, Keskitalo A, Vuorikoski H, Pietilä S, Elo LL, Munukka E, et al. Chronic nonbacterial prostate inflammation in a rat model is associated with changes of gut microbiota that can be modified with a galactoglucomannan-rich hemicellulose extract in the diet. BJU Int. 2019;123:899–908.
pubmed: 30256506
doi: 10.1111/bju.14553
Minutoli L, Rinaldi M, Marini H, Irrera N, Crea G, Lorenzini C, et al. Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia. Int J Mol Sci. 2016;17:1311.
pubmed: 27529214
pmcid: 5000708
doi: 10.3390/ijms17081311
Ratajczak W, Mizerski A, Rył A, Słojewski M, Sipak O, Piasecka M, et al. Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS). Aging (Albany NY). 2021;13:10934–54. https://doi.org/10.18632/aging.202968 .
Takezawa K, Fujita K, Matsushita M, Motooka D, Hatano K, Banno E, et al. The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement. Prostate. 2021;81:1287–93.
pubmed: 34516694
doi: 10.1002/pros.24223
Holland B, Karr M, Delfino K, Dynda D, El-Zawahry A, Braundmeier-Fleming A, et al. The effect of the urinary and fecal microbiota on lower urinary tract symptoms measured by the international prostate symptom score: analysis utilizing next-generation sequencing. BJU Int. 2020;125:905–10. https://doi.org/10.1111/bju.14972 .
Heintz-Buschart A, Wilmes P. Human gut microbiome: function matters. Trends Microbiol. 2018;26:563–74.
pubmed: 29173869
doi: 10.1016/j.tim.2017.11.002
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83–90.
doi: 10.1001/jama.1993.03510010089036
Salonia A, Castagna G, Saccà A, Ferrari M, Capitanio U, Castiglione F, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. J Sex Med. 2012;9:2708–15.
pubmed: 22897643
doi: 10.1111/j.1743-6109.2012.02869.x
Corona G, Petrone L, Mannucci E, Magini A, Lotti F, Ricca V, et al. Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl. 2006;27:795–801.
pubmed: 16809271
doi: 10.2164/jandrol.106.000638
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.
pubmed: 8254833
doi: 10.1016/S0022-5347(17)34871-1
Capogrosso P, Colicchia M, Ventimiglia E, Castagna G, Clementi MC, Suardi N, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man—worrisome picture from the everyday clinical practice. J Sex Med. 2013;10:1833–41.
pubmed: 23651423
doi: 10.1111/jsm.12179
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology Guidelines on Sexual and Reproductive Health—2021 update: male sexual dysfunction. Eur Urol. 2021;80:333–57.
pubmed: 34183196
doi: 10.1016/j.eururo.2021.06.007
Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, et al. The association between gut microbiome and erectile dysfunction: a community-based cross-sectional study in Japan. Int Urol Nephrol. 2020;52:1421–8.
pubmed: 32193686
doi: 10.1007/s11255-020-02443-9
Nagashima K, Hisada T, Sato M, Mochizuki J. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol. 2003;69:1251–62.
pubmed: 12571054
pmcid: 143637
doi: 10.1128/AEM.69.2.1251-1262.2003
Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. Development of a prokaryotic universal primer for simultaneous analysis of bacteria and archaea using next-generation sequencing. PLoS One. 2014;9:e105592.
pubmed: 25144201
pmcid: 4140814
doi: 10.1371/journal.pone.0105592
Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5:14.
pubmed: 28143587
pmcid: 5286796
doi: 10.1186/s40168-016-0222-x
Barlow GM, Yu A, Mathur R. Role of the gut microbiome in obesity and diabetes mellitus. Nutr Clin Pract. 2015;30:787–97.
pubmed: 26452391
doi: 10.1177/0884533615609896
Kanbay M, Onal EM, Afsar B, Dagel T, Yerlikaya A, Covic A, et al. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. Int Urol Nephrol. 2018;50:1453–66.
pubmed: 29728993
doi: 10.1007/s11255-018-1873-2
Li H, Qi T, Huang Z, Ying Y, Zhang Y, Wang B. et al. Relationship between gut microbiota and type 2 diabetic erectile dysfunction in Sprague-Dawley rats. J Huazhong Univ Sci Technolog Med Sci. 2017;37:523–30.
pubmed: 28786059
doi: 10.1007/s11596-017-1767-z
Tirandaz H, Ebrahim-Habibi M-B, Moradveisi B, Raoofi S, Salehi-Najafabadi A, Mohammadi E. Microbiota potential for the treatment of sexual dysfunction. Med Hypotheses. 2018;115:46–49.
pubmed: 29685195
doi: 10.1016/j.mehy.2018.03.021
Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084–8.
pubmed: 23328391
doi: 10.1126/science.1233521
Markle JG, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes. 2014;5:485–93.
pubmed: 25007153
doi: 10.4161/gmic.29795
Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39:400–12.
pubmed: 23973225
doi: 10.1016/j.immuni.2013.08.013
Dinan TG, Cryan JF. Regulation of the stress response by the gut microbiota: Implications for psychoneuroendocrinology. Psychoneuroendocrinology. 2012;37:1369–78.
pubmed: 22483040
doi: 10.1016/j.psyneuen.2012.03.007
Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105:755–64.
pubmed: 20974015
doi: 10.1017/S0007114510004319
Esposito K, Giugliano F, Ciotola M, De Sio M, D’Armiento M, Giugliano D. Obesity and sexual dysfunction, male and female. Int J Impot Res. 2008;20:358–65.
pubmed: 18401349
doi: 10.1038/ijir.2008.9
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444:1022–3.
pubmed: 17183309
doi: 10.1038/4441022a
Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455:1109–13.
pubmed: 18806780
pmcid: 2574766
doi: 10.1038/nature07336
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.
pubmed: 18305141
doi: 10.2337/db07-1403
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
pubmed: 23023125
doi: 10.1038/nature11450
Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331–40.
pubmed: 25870193
doi: 10.1161/HYPERTENSIONAHA.115.05315
Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens. 2015;24:403–9.
pubmed: 26125644
pmcid: 4578629
doi: 10.1097/MNH.0000000000000149